Qkine and Sartorius partnership delivers a complete workflow solution for the analysis of advanced cell models

  • Sartorius to commercialize Qkine growth factors and cytokines as part of a complete workflow solution for stem cell and organoid research
  • Cell type-specific application data on Sartorius instruments streamline process and speed up time to results
  • This collaboration supports a larger initiative to enable rapid advancement in the science of advanced cell models

Cambridge, UK, 6th July 2023

Qkine HQ and Sartorius packaging

Qkine, a manufacturer of animal-free, highly bioactive, and innovative proteins, is delighted to announce its collaboration with Sartorius, a global life science group, to supply growth factors and cytokines for stem cell and organoid research, as part of a comprehensive workflow solution.

Our goal at Sartorius has always been to simplify progress in life science research by bringing our customers end-to-end workflow solutions for core and emerging applications. We’re embracing the promise of advanced culture systems for disease modelling and expanding our portfolio to support this rapidly growing field,” said Fiona Coats, Head of Marketing at Sartorius’ Lab Products and Services division. “We want to provide not just the tools and reagents, but also the validation data scientists need to drive their research forward with confidence.”

Sartorius is a leading provider of laboratory solutions for life science research and drug discovery. Its cell analysis portfolio includes reagents, assays, and enabling instrument technologies, such as live-cell imaging and automated cell culture, for biologics discovery, cell line development, and advanced cell model applications.

Qkine animal-free growth factors and cytokines will be provided as part of Sartorius’s rapidly expanding stem cell research portfolio that includes cutting-edge equipment and high-performance reagents. Additionally, customers will have access to application data for the use of these products with different cell types on Sartorius instrumentation for live-cell imaging and analysis.

“Sartorius has an excellent reputation in the market for supporting scientists working with complex cell models with cutting-edge tools. We also have shared values on the importance of providing our customers with quality products that enable them to maximise the impact of their research. This is an excellent collaboration to combine Qkine high-purity growth factors and cytokines with Sartorius’ complementary product portfolio to support advances in stem cell and organoid science.” added Catherine Elton, CEO and co-founder of Qkine.

Qkine and Sartorius are committed to advancing scientific research and empowering scientists with the tools they need to make rapid breakthroughs in fields such as regenerative medicine and drug discovery, where stem cell models are at the forefront of innovation. For more information about Qkine and Sartorius, please visit their respective websites: www.qkine.com and www.sartorius.com.

About Qkine

Qkine manufactures high-purity, animal-free growth factors, cytokines, and other complex proteins for life science applications including stem cell and organoid culture. Based in Cambridge, UK,

Qkine combines proprietary production processes with protein engineering technology to tackle fundamental biological, quality and scale-up challenges to provide more reliable tools for research and bio-manufacturing. Please visit qkine.com for more information or follow us on LinkedIn for the latest company updates.

About Sartorius

The Sartorius Group is a leading international partner of life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes.

The Bioprocess Solutions division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications and vaccines safely, rapidly, and economically.

The company based in Goettingen, Germany, has a strong global reach with around 60 production and sales sites worldwide. Sartorius delivers significant organic growth and regularly expands its portfolio through the acquisition of complementary technologies. In fiscal 2022, the company generated sales revenue of around 4.2 billion euros. At the end of 2022, around 16,000 employees were working for customers around the globe. www.sartorius.com

Media contact
Alison Rawlinson
Head of Marketing

View the Press Release on Business Wire.